Targeting sex steroids to improve the response to bladder cancer immunotherapy

针对性类固醇来改善膀胱癌免疫治疗的反应

• 批准号: 444205
• 负责人: Toren Paul
• 金额: $ 59.91万
• 依托单位: Universit Laval
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-04-01 至 2026-04-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=444205&lang=en
• 关键词: Anti-Androgens; Bacille-Calmette Guérin Therapy; Bladder Cancer; Immunotherapy; Sex Steroids; Tumor Microenvironment

Bladder cancer is the 5th most common cancer affecting Canadians. There are notable differences in the incidence between sexes, with bladder cancer four times more common in men, though tumors in women tend to be more aggressive. However, the reasons why

膀胱癌是影响加拿大人的第五大常见癌症。性别之间的发病率存在显着差异，男性膀胱癌的发病率是男性的四倍，尽管女性肿瘤往往更具侵略性。然而，